Short answer

Rezolute, Inc. (RZLT) filed its fiscal 2026 10-K annual report with the SEC on Sep 24, 2026.

Top risk flagged: Regulatory risk: FDA review of supplemental data for ersodetug post-sunRIZE trial may require a new randomized study, delaying commercialization

FY2026 key financial metrics · XBRL

Source: XBRL data from the Rezolute, Inc. (RZLT) FY2026 10-K on SEC EDGAR. USD.

AI summary of each section, grounded in the filing text

Core business: Late-stage rare disease company developing therapies for refractory hypoglycemia caused by various hyperinsulinism forms
New emphasis: Phase 3 results for ersodetug in congenital HI showed significant CGM-based hypoglycemia improvements despite missing primary endpoint
Strategic update: FDA review ongoing uniquely outside formal meetings, with encouragement to submit comprehensive data for regulatory path determination
Quantitative highlight: R&D expense $53.8M in 2026 down from $61.5M in prior year; 58 full-time employees, all US-based
Noteworthy fact: Six of eight participants met primary endpoint in ongoing Phase 3 tumor HI trial, with notable discontinuation of intravenous glucose

Revenue nil for 2026 and 2025; no commercial products, no meaningful revenue since inception
Net loss $77.6M in 2026 vs $74.4M in 2025; operating expenses increased 4% to $83.0M; R&D down 13% to $53.8M; G&A up 59% to $29.2M
Best performing: R&D expenses down $7.7M (mainly $9.3M manufacturing cost reduction); worst performing: G&A expenses up $10.8M driven by $5.7M compensation and $4.6M business development costs
Cash & equivalents $10.6M, marketable securities $97.2M; operating cash outflow $64.6M; investing cash outflow $21.1M; financing inflow only $2.3M in 2026 (vs $107.3M in 2025 from equity financings)
Management expects sufficient capital for 12 months; key near-term events include upLIFT Phase 3 topline data in 2026, FDA review of sunRIZE data ongoing with no timeline, and potential BLA submission mid-2027 for ersodetug

Regulatory risk: FDA review of supplemental data for ersodetug post-sunRIZE trial may require a new randomized study, delaying commercialization
Macroeconomic risk: Potential supply chain delays and cost increases due to inflation, tariffs, and global conflicts impacting raw material availability
Supply chain risk: Dependence on a limited number of third-party suppliers with no commercial production agreements for raw materials and drug manufacturing
Competitive risk: Equity investigations and stock price decline following sunRIZE trial failure may hurt financing and competitive positioning
Financial risk: Net losses $77.6M FY26, $74.4M FY25 with only $10.6M cash and $97.2M debt securities, requiring additional capital within 12 months to sustain operations

Generated from the filing text; verify against the original. How to read a 10-K

Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.